Pharnext to Attend Jefferies 2016 London Healthcare Conference

Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), a French biopharmaceuticals company developing an advanced portfolio of products in the field of neurodegenerative diseases, announces today its participation at the Jefferies 2016 London Healthcare Conference taking place November 16-17 at the Waldorf Hotel in London, UK.
This Conference is the largest healthcare meeting in Europe dedicated to
companies from around the world: biotechnologies, pharmaceuticals,
generics, medtechs and healthcare services. Last year, the Jefferies
conference hosted over 300 participating companies, 1,200 attendees and
3,700 B2B and investor meetings.
ABOUT PHARNEXT
Pharnext is an advanced clinical stage biopharmaceutical company founded
by renowned scientists and entrepreneurs including Professor Daniel
Cohen, a pioneer in modern genomics. Pharnext focuses on
neurodegenerative diseases and has two lead products in clinical
development: PXT3003 is currently in an international Phase 3 trial for
the treatment of Charcot-Marie-Tooth disease type 1A and benefits from
orphan drug status in Europe and the United States. Pharnext is the
pioneer of a new drug discovery paradigm: PLEOTHERAPIE®. Pharnext
identifies and develops synergetic combinations of drugs that are
already being used for other diseases. These PLEOMEDICAMENT® are
developed at new lower doses and repositioned into new indications. The
PLEOMEDICAMENT® offer several key advantages: efficacy, safety, and
intellectual property including several composition of matter patents
already granted. The Company is supported by a world-class scientific
team.
The company Pharnext is listed on Euronext Alternext Stock Exchange in
Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com.